Clinical trials: Pulmonary Disease, Chronic Obstructive
Asthma, COPD
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway
This is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or COPD who are treated with budesonide-formoterol.
- Trial name
- BufoSwitch (NCT04663386)
- Testing
- Budesonide-Formoterol
- Where
- Norway
- Volunteers
- 29 people
- Sponsor
- Orion Corporation, Orion Pharma
Chronic Obstructive Pulmonary Disease
Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD
The overall objective of this study was to assess the efficacy and safety of GP MDI relative to placebo in Japanese subjects with moderate to severe COPD.
- Trial name
- NCT03256552
- Testing
- Glycopyrronium MDI 28.8 micrograms, Glycopyrronium MDI 14.4 micrograms, Glycopyrronium MDI 7.2 micrograms
- Where
- 18 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease
This Study Will Investigate How Food and Age Effect the Way the Body Handles the AZD5069 Drug Given as a Oral Dose
AZD5069 is a new drug being tested for the possible treatment of people with chronic obstructive pulmonary disease (COPD). This is not the first time that AZD5069 will be administered to humans in clinical trials.
- Trial name
- NCT01083238
- Testing
- AZD5069
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD, Interstitial Lung Disease
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day.
- Trial name
- NCT03044431
- Testing
- Cell therapy
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Lung Institute
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
- Conditions
- Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
- Trial name
- NCT00064402
- Testing
- arformoterol tartrate inhalation solution, Salmeterol
- Where
- 65 sites in United States
- Volunteers
- 741 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD
This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation…
- Trial name
- DB2113361 (NCT01313637)
- Testing
- GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg
- Where
- 157 sites in United States, Belgium and 12 more
- Volunteers
- 1,493 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.
The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with different level of renal impairment in…
- Trial name
- TRIPLE10 (NCT02040597)
- Testing
- Beclometasone/Formoterol/Glycopyrrolate
- Where
- 2 sites in Poland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, Pulmonary Disease, Chronic Obstructive
Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction
Assessment of the inhalation profiles of four dry powder inhalers in patients with variable degrees of lung obstruction
- Trial name
- NCT01033669
- Testing
- CRC-749, Diskus, Twisthaler
- Where
- Germany
- Volunteers
- 57 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
To evaluate the effect of Mucomyst nebulizer therapy on improvement in symptoms and quality of life in COPD patients with difficulty of expectoration.
- Trial name
- NCT05102305
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Asthma, COPD
Observational Study of Obstructive Lung Disease (NOVELTY)
The NOVEL Observational longiTudinal studY (NOVELTY) is an observational study of obstructive lung disease and is a multi-country, multi-centre, prospective, longitudinal cohort study which will recruit patients with a diagnosis…
- Conditions
- Asthma, COPD, Chronic Obstructive Pulmonary Disease
- Trial name
- NOVELTY (NCT02760329)
- Testing
- Blood draw, Urine, Lung function measurements
- Where
- 331 sites in United States, Argentina and 17 more
- Volunteers
- 12,255 people
- Sponsor
- AstraZeneca
COPD, Respiratory Disease
Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD
Vapendavir (VPV) is potent virostatic antiviral agent active against all known enterovirus species. VPV binds to the viral capsid, thereby inhibiting viral attachment to the target cell and, independently, preventing release of…
- Conditions
- COPD, Respiratory Disease, Lower Respiratory Disease, Pulmonary Disease
- Trial name
- NCT05962645
- Testing
- Vapendavir
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Altesa Biosciences, Inc.
COPD
AZD8683 Multiple Dose Study in Healthy Volunteers and Chronic Obstructive Pulmonary Disease (COPD) Patients
This study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending inhaled doses of AZD8683 in Healthy volunteers and repeated inhalation of one dose level of AZD8683 in patients…
- Trial name
- NCT01584739
- Testing
- AZD8683
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy of Aclidinium Bromide Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of inhaled aclidinium bromide in moderate to severe COPD patients.
- Trial name
- NCT00868231
- Testing
- Aclidinium bromide 400 μg bid, Tiotropium 18 μg once-daily
- Where
- 2 sites in Germany
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
COVID-19, Chronic Bronchitis
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in Patients Aged ≥60 Years With Chronic Bronchitis and COPD
Evaluation of immunogenicity and safety of the subjects aged 60 years and above with chronic bronchitis and chronic obstructive pulmonary disease recruited to receive the schedule of three doses of inactivated COVID-19 vaccine on…
- Conditions
- COVID-19, Chronic Bronchitis, Copd
- Trial name
- NCT05075057
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Pulmonary Disease, Chronic Obstructive
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive…
- Trial name
- NCT01376245
- Testing
- fluticasone furoate/vilanterol
- Where
- 34 sites in China, Philippines and 2 more
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three…
- Trial name
- NCT07267130
- Testing
- TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients
This study will assess the effects of single oral doses of SB681323 and prednisolone on biomarkers in induced sputum and blood COPD patients
- Trial name
- NCT00380133
- Testing
- SB681323, Prednisolone
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive, Exercise
Tiotropium In Exercise
The objective of this study is to evaluate the effects on exercise duration of 96 weeks treatment with 18 mcg tiotropium (Spiriva HandiHaler) daily as compared to placebo, in patients with COPD.
- Trial name
- NCT00525512
- Testing
- tiotropium 18 mcg
- Where
- 62 sites in United States, Argentina and 9 more
- Volunteers
- 519 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.
This study will investigate the safety and tolerability of inhaled doses of GSK233705 with a new formulation.
- Trial name
- NCT00453687
- Testing
- GSK233705
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment
This study will assess the safety and pharmacokinetics of inhaled GSK573719 and GSK573719/vilanterol combination in healthy subjects and in subjects with severe renal impairment.
- Trial name
- NCT01571999
- Testing
- Inhaled GSK573719, Inhaled GSK573719/vilanterol
- Where
- 2 sites in Czechia, Hungary
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline